LVCLF Stock UPDATES Living Cell Technologies Limited (LVCLF)

New Post Public Reply Private Reply Replies (0) Message Board

Sep 10, 2014 at 2:27 PM

Living Cell Technologies Limited (LVCLF) 0.0596 $LVCLF

Hearing Disorders - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7w63tx/hearing_disorders) has announced the addition of the "Hearing Disorders - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hearing Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hearing Disorders and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hearing Disorders - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hearing Disorders pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Adherex Technologies - Quark Pharmaceuticals - Novartis - Living Cell Technologies - Fate Therapeutics - Sound Pharmaceuticals - Pharmicell - Otologic Pharmaceutics - UniQure - AudioCure For more information visit http://www.researchandmarkets.com/research/7w..._disorders

'First-in-man' Implant of Regenerative Cell Therapy in Parkinson's Disease
PR Newswire - Thu Sep 19, 9:36PM CDT
Living Cell Technologies Limited (LCT) today announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL(R) - a potential treatment for Parkinson's disease.

Hemophilia - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rvbm6c/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H2 2013" report to their offering. 'Hemophilia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Scope - A snapshot of the global therapeutic scenario for Hemophilia. - A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Biogen Idec Inc. AstraZeneca PLC Nektar Therapeutics Cangene Corporation Lentigen Corporation Sangamo BioSciences, Inc. Pharming Group N.V. Novo Nordisk A/S BioMarin Pharmaceutical Inc. Chugai Pharmaceutical Co. Ltd Dong-A Pharmaceutical Co., Ltd. GTC Biotherapeutics, Inc. Octapharma AG Pain Therapeutics, Inc. Pfizer Inc. Bayer AG Living Cell Technologies Limited PROLOR Biotech, Inc. ReGenX Biosciences, LLC Alnylam Pharmaceuticals, Inc CSL Limited and many more... For more information visit http://www.researchandmarkets.com/research/rvbm6c/hemophilia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Huntington's Disease - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Huntington's Disease
M2 - Thu Sep 05, 9:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6nbttk/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Huntington's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. Huntington's Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Huntington's Disease. - A review of the Huntington's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Huntington's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 - ACADIA Pharmaceuticals Inc. - Accera, Inc. - Auspex Pharmaceuticals - BrainStorm Cell Therapeutics Inc. - Ceregene, Inc. - CrystalGenomics, Inc. - GW Pharmaceuticals plc - Galenea Corp. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Ipsen S.A. - Isis Pharmaceuticals, Inc. - KineMed, Inc. - Living Cell Technologies Limited - Neuralstem, Inc. - Omeros Corporation - Oryzon - Pfizer Inc. - Prana Biotechnology Limited - Raptor Pharmaceuticals Corp. - SCYNEXIS, Inc. - Siena Biotech S.p.A. - Suven Life Sciences Ltd. - Teva Pharmaceutical Industries Limited - The Avicena Group, Inc. - Varinel, Inc. - Vertex Pharmaceuticals Incorporated - Vybion, Inc. - Wellstat Therapeutics Corporation For more information visit http://www.researchandmarkets.com/research/6n...untingtons About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Huntington's Disease - Pipeline Review, H1 2013
M2 - Wed Apr 17, 4:33AM CDT
Research and Markets has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2013" report to their offering. 'Huntington's Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Huntington's Disease. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Huntington's Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Huntington's Disease pipeline depth and focus of Indicatio

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Athlete Threats: Public Info Fuels Security Risks

Public Exposure: The New Athlete Achilles' Heel Imagine sitting on millions while living in a glass house. That's the kind of predicament today's athletes find themselves in, thanks to the treasure trove of public information spilling their personal lives all over the internet. According to the latest Hush Intelligence Athlete Threat Report 2026, this very exposure has...

Comparent Unveils Key Insights with Top 100 List

The Ebb and Flow of Vacation Rental Giants Ever noticed how some industries just sneak up and suddenly transform landscapes? Vacation rental management is one of those sneaky offenders. At the forefront of keeping tabs on this bustling sector, Comparent just dropped a meaty second annual roster—the Comparent 100—showcasing the biggest players flexing their muscles in...

Gateway Unveils All-In-One Award Travel Platform

Transforming Loyalty with point.me's Gateway Here's the deal: the loyalty program game just changed. Point.me rolled out this slick beast called Gateway, and it's weaving award travel booking right into your everyday banking apps. That's right, ditch those clunky third-party sites, because now you can browse, compare, transfer, and book your award travel directly from...

Fresh Leadership at Master Group: Langelier Steps In

Changing of the Guard: A Calculated Move It's not every day you see a company make a move as calculated and thoughtful as the one the Master Group just pulled. Rémy Langelier is set to transition into the shoes of CEO by early 2027, fresh off the heels of Louis St-Laurent. This isn't just any executive shuffle, folks—it's a strategic baton pass spawning an investment...

Mitsubishi's Q3 Sales: SUVs Up, Mirage Out

You ever notice how the market treats innovation and tradition like they’re these ever-spinning plates in a circus act? Take Mitsubishi Motors North America (MMNA). Their third-quarter report's got me both nodding in approval and scratching my head. Sure, they sold 18,543 vehicles—down 5.6% from the previous year. But don’t write 'em off just yet. The slumping...

Neutonic Sets Sights on U.S. with Walmart Expansion

Neutonic Embarks on Major Expansion with Walmart Well, here we go. Neutonic is stepping up to the big leagues by planting its flag in nearly 1,000 Walmart stores across the U.S. This move lands them right in the thrumming heart of Walmart's new Mood & Mind beverage set. It's about time this brand brings its functional beverages to American shoppers already drained by...

Nelson-Jameson Boosts Cold Storage in California Move

An Icy Boost for the West Coast Dairy Player Every now and then, a company gets its cold storage game just right. Nelson-Jameson has added fresh muscle to its Turlock facility in California, making waves with serious logistical upgrades. The company's dogged pursuit of better operational efficiency in dairy processing isn't just about bragging rights. It's plain old good...

Managed Connectivity: Key to Modern Multifamily Living

Connectivity Runs the Modern Show Imagine moving into a shiny new apartment, where the biggest hassle isn't unpacking boxes but ensuring your gadgets get online smoothly. That's the reality of today's multifamily living, where the internet is more than a utility—it's the backbone of modern life. And if you think it's just about offering internet access, you're missing...

Wisconsin Chefs Transform Pizza with Crave Brothers Cheese

Reimagining Pizza with Wisconsin's Best Cheeses It's not every day you see a pizza challenge that turns a staple of Friday nights into a gastronomic showcase. But that's exactly what's happening in Wisconsin as chefs flex their creativity using Crave Brothers Farmstead Cheese. This is no ordinary cheese-and-pepperoni affair—these culinary pros are cooking up pizzas with...

MiniCo's New Desk: A Game Changer for E&S Market

A New Chapter in Industrial Casualty Look out, folks! MiniCo Insurance Agency is making waves with its latest launch. They're teaming up with Lloyd's of London, not to sell fish and chips, but to bring something groundbreaking in the insurance space—an industrial casualty trading desk. And if you’re raising an eyebrow wondering why this matters, let me break it down...